Global Phase III programme for D-Pharm's neurorotective extended to S Korea
This article was originally published in Scrip
Executive Summary
D-Pharm's local licensee Yungjin Pharmaceutical has received approval from South Korea's FDA to begin a Phase III trial in the country with D-Pharm's neuroprotective and lead product candidate DP-b99.